Impacting News
Premium
Anavex Life Sciences: Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial
Anavex Life Sciences Anavex Life Sciences ( AVXL ) presented new data from the Phase IIb/III study showing that blarcamesine (ANAVEX®2-73), once daily orally, demonstrates pre-specified clinical effic...
P
Prohost Biotech
1 min read
15
0
Unlock Premium Content
This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.
Unlimited articles
Expert analysis
Research reports
Comments (0)
Please sign in to join the discussion